Polo-like
kinase 1 (Plk1) is a serine/threonine kinase that plays
a key role during the cell cycle by regulating mitotic entry, progression,
and exit. Plk1 is overexpressed in a variety of human cancers and
is essential to sustained oncogenic proliferation, thus making Plk1
an attractive therapeutic target. However, the clinical efficacy of
Plk1 inhibition has not emulated the preclinical success, stressing
an urgent need for a better understanding of Plk1 signaling. This
study addresses that need by utilizing a quantitative proteomics strategy
to compare the proteome of BRAFV600E mutant melanoma cells
following treatment with the Plk1-specific inhibitor BI 6727. Employing
label-free nano-LC–MS/MS technology on a Q-exactive followed
by SIEVE processing, we identified more than 20 proteins of interest,
many of which have not been previously associated with Plk1 signaling.
Here we report the down-regulation of multiple metabolic proteins
with an associated decrease in cellular metabolism, as assessed by
lactate and NAD levels. Furthermore, we have also identified the down-regulation
of multiple proteasomal subunits, resulting in a significant decrease
in 20S proteasome activity. Additionally, we have identified a novel
association between Plk1 and p53 through heterogeneous ribonucleoprotein
C1/C2 (hnRNPC), thus providing valuable insight into Plk1’s
role in cancer cell survival.